Abstract:Heterozygous H3.3 K27M mutations are central to the pathogenesis of diffuse midline gliomas (DMG), causing a global reduction in H3K27 trimethylation (H3K27me3) and subsequent epigenetic dysregulation. H3.3 contains a unique Serine 31 (S31) phosphorylation site crucial for mitotic checkpoint regulation. In DMG cells, reduced mitotic S31 phosphorylation correlates with chromosomal instability and aneuploidy. Using a mouse model, we demonstrate that both H3.3K27M and H3.3S31A mutations promote high-grade glioma development, whereas wild-type H3.3 does not. Importantly, S31A, which maintains normal K27me, suggests that S31 phosphorylation loss alone is oncogenic. The H3.3K27M mutation disrupts epigenetic regulation by inhibiting the Polycomb Repressive Complex 2 (PRC2), leading to decreased H3K27me3 and unintended gene induction. Concurrently, K27M exerts a compensatory repressive effect on the transcriptome, mediated by reduced S31 phosphorylation, independent of PRC2 activity. Using CRISPR-engineered isogenic DMG cells and analyzing the transcriptome and chromatin accessibility with RNA-seq and ATAC-seq, we found that the K27M mutation produces a balanced gene expression profile, while PRC2 loss primarily leads to gene induction. Notably, cells with S31A mutations also maintain this balanced profile, linking the PRC2-independent effect of K27M to reduced S31 phosphorylation. Conversely, cells with wild-type K27 but S31A mutation show a repressive genomic state, evidenced by an up/down gene ratio of 0.75, owing to functional PRC2. We further show that the genes uniquely dysregulated by K27M or S31A, independent of PRC2, overlap significantly, with dysregulated genes displaying altered chromatin accessibility. This suggests that the effect of K27M and S31A mutations on gene regulation is primarily due to changes in chromatin state. This complex interplay points to targeting K27M-associated pathways, particularly S31 phosphorylation, as a promising therapeutic avenue in DMG, a malignancy with fewer effective treatments and dismal prognosis.

Mutated KLF4(K409Q) in meningioma binds STRs and activates FGF3 gene expression

KLF4 is a Tumor Suppressor in Anaplastic Meningioma Stem-Like Cells and Human Meningiomas

Putative Tumor-Suppressive Function of Krüppel-Like Factor 4 in Primary Lung Carcinoma

KLF4 regulates endothelial-masenchymal transition and suppresses meningioma

KLF4 Downregulates Htert Expression and Telomerase Activity to Inhibit Lung Carcinoma Growth.

Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits

Krüppel-like Factor 4 (KLF4) Induces Mitochondrial Fusion and Increases Spare Respiratory Capacity of Human Glioblastoma Cells

Long Noncoding RNA LINC00052 Suppressed the Proliferation, Migration and Invasion of Glioma Cells by Upregulating KLF6.

Promoter Hypermethylation-mediated Inactivation of LRRC4 in Gliomas

H3F3A K27M Mutations Drives a Repressive Transcriptome by Modulating Chromatin Accessibility, Independent of H3K27me3 in Diffuse Midline Glioma

Epco-04. H3F3A K27M Mutation Drives A Repressive Transcriptome Via Reduced Serine 31 Phosphorylation By Modulating Chromatin Accessibility, Independent Of H3K27Me3 In Diffuse Midline Glioma

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma

Comprehensive Molecular Profiling Identifies FOXM1 As a Key Transcription Factor for Meningioma Proliferation.

Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression.

The Pathognomonic FOXL2 C134W Mutation Alters DNA-Binding Specificity

Alternative splicing of Kruppel‐like factor 4 plays a pivotal role in human tumorigenesis

Krüppel-like Factor 4 Contributes to the Pathogenesis of Mantle Cell Lymphoma.

Epigenome programing by H3.3K27M mutation creates a dependence of pediatric glioma on SMARCA4

Krüppel-like Factor 4 Regulates Blood-Tumor Barrier Permeability Via ZO-1, Occludin and Claudin-5.

Krüppel‐like Factor 4 Functions As a Tumor Suppressor in Cervical Carcinoma

KLF4 transcription factor in tumorigenesis